TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02907177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of matching placebo administered orally once daily in the morning
Study: NCT04578301

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT00396071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: vildagliptin 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT02566213

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study: NCT02851394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Study: NCT02566213

Intervention type: OTHER
Group type: OTHER
Intervention: Motor skills measurements
Description: * the kinematics measurements of the right hand with a motion analysis system;~* the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;~* the measurement of position of the moved object with an inductive position encoder.
Study: NCT03224728

Intervention type: DEVICE
Intervention: intraocular lens
Study: NCT02344667

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Study: NCT03760432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Custom Corneal Collagen Cross-Linking
Description: Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
Study: NCT00688350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral feedback
Description: The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
Study: NCT03105180

Intervention type: OTHER
Intervention: A mixture of 2.7% sorbitol-0.54% mannitol solution
Description: Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
Study: NCT03353649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Now vs. Later Cue
Description: As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Now vs. Later Cue
Description: As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
Study: NCT01324011

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adult diabetes family-based weight loss intervention
Description: Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adult diabetes family-based weight loss intervention
Description: Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
Study: NCT00914732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Vaccinia vaccine liquid formulation delivered at lower dose \[2x10\^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose\] by intradermal (ID) route on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
Study: NCT03658395

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sacrocolopopexy
Description: The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
Study: NCT01381055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
Study: NCT03105180

Intervention type: OTHER
Intervention: A mixture of 2.7% sorbitol-0.54% mannitol solution
Description: Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.

Intervention type: OTHER
Intervention: A mixture of 2.7% sorbitol-0.54% mannitol solution
Description: Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
Study: NCT02009553

Intervention type: OTHER
Intervention: Information sheet

Intervention type: OTHER
Intervention: No information sheet
Study: NCT03658395

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior repair
Description: The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
Study: NCT03740919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT01059617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' FluLaval®
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' FluLaval®
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Intramuscular injection
Study: NCT03213769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical coenzyme Q10 gel
Description: Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
Study: NCT02335242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets (resembling Revatio)
Study: NCT03063346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate high dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate low dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01059617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
Description: Intramuscular injections
Study: NCT01307501

Intervention type: DEVICE
Group type: OTHER
Intervention: Cryoablation
Description: Application of extremely cold temperatures to the identified tumor(s).
Study: NCT01475526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: El Valor de Nuestra Salud Store Intervention
Description: Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
Study: NCT04679129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42
Description: Oral tablets
Study: NCT03213769

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carpabol gel
Description: placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
Study: NCT04679129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT04431102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILATES METHOD
Description: It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day.
Study: NCT01164059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 10, 15, or 20 mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol
Description: Flupentixol 6, 9, or 12 mg / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine 400, 600, or 800 mg / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole 10, 15, or 20 mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol 3, 4.5, or 6 mg / day
Study: NCT04824560

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blood pressure education
Description: One page teaching protocol performed by pharmacy students; phone follow-up
Study: NCT04024852

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
Study: NCT04511923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulised heparin
Description: Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
Study: NCT05063318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin alone
Description: The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin alone
Description: The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin+Itraconazole co-administration
Description: The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin+Itraconazole co-administration
Description: The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
Study: NCT03203746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene + SRP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP only
Study: NCT03542253

Intervention type: PROCEDURE
Intervention: Surgery
Description: After surgical treatment, pathological specimens were extracted to obtain pathological results
Study: NCT01987843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Middle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-High
Study: NCT03120624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo image-guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo image-guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Tetrafluoroborate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Tetrafluoroborate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo TFB-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo TFB-PET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Description: Given IV
Study: NCT01987843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03470896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preanesthesia teleconsultation
Description: According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
Study: NCT03120624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sodium Pertechnetate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sodium Pertechnetate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo mouth rinse, buccal swab, urine, and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo mouth rinse, buccal swab, urine, and blood sample collection
Study: NCT05037396

Intervention type: DRUG
Intervention: Brolucizumab
Description: Participants received brolucizumab injection during the index period
Study: NCT04274738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Description: Mavorixafor capsules will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules will be administered per dose and schedule specified in the arm.
Study: NCT04471428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be administered orally, once daily at a dose of 40 mg on Days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered by IV infusion at a starting dose of 75mg/m2 on Day 1 of each 21-day cycle.
Study: NCT03283449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: PET scanner for brain imaging
Study: NCT03903185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir / Sofosbuvir Oral Product
Description: 45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir / Sofosbuvir Oral Product
Description: 45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
Study: NCT02270125

Intervention type: PROCEDURE
Intervention: Mucotomy
Description: Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia

Intervention type: PROCEDURE
Intervention: Mucotomy
Description: Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
Study: NCT03849300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic walking exercise program group 1
Description: 12 week aquatic walking exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic walking exercise program group 2
Description: 12 week aquatic walking exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based walking exercise group
Description: 12 week land-based walking exercise program
Study: NCT04327349

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent Plasma
Description: Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
Study: NCT05618717

Intervention type: DEVICE
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation using irrigated ablation catheter

Intervention type: DEVICE
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation using irrigated ablation catheter
Study: NCT04528368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.